Published in Lancet Neurol on January 10, 2008
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature (2015) 4.03
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology (2012) 2.49
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2011) 1.57
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging (2014) 1.49
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem (2010) 1.28
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol (2008) 1.25
Partial volume correction in quantitative amyloid imaging. Neuroimage (2014) 1.24
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging (2014) 1.17
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry (2012) 1.12
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol (2008) 1.11
Development of positron emission tomography β-amyloid plaque imaging agents. Semin Nucl Med (2012) 1.09
Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging (2009) 1.08
Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord (2012) 1.08
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging (2011) 1.06
Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One (2012) 1.04
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc (2011) 0.99
Evaluation of [(11)C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles. ACS Med Chem Lett (2012) 0.99
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol (2014) 0.94
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med (2011) 0.94
BODIPY-based molecular probe for imaging of cerebral β-amyloid plaques. ACS Chem Neurosci (2012) 0.93
Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med (2010) 0.93
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci (2012) 0.93
Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.90
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2013) 0.90
Imaging in Alzheimer's disease. Dialogues Clin Neurosci (2009) 0.90
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Beta-amyloid imaging with florbetaben. Clin Transl Imaging (2015) 0.89
Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-β oligomers and no plaque pathology. Mol Neurodegener (2014) 0.89
Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One (2013) 0.89
Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer's brains. ACS Chem Neurosci (2011) 0.88
Radiosyntheses using fluorine-18: the art and science of late stage fluorination. Curr Top Med Chem (2014) 0.88
A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques. ACS Med Chem Lett (2011) 0.88
PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta (2011) 0.87
Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide. Mol Neurodegener (2009) 0.86
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA). J Med Chem (2011) 0.86
Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun (2014) 0.86
Mapping brain beta-amyloid. Curr Opin Neurol (2009) 0.86
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85
Synthesis and evaluation of novel chalcone derivatives with (99m)Tc/Re complexes as potential probes for detection of β-amyloid plaques. ACS Chem Neurosci (2010) 0.85
[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiol Dis (2011) 0.85
Recent advances in imaging Alzheimer's disease. J Alzheimers Dis (2013) 0.85
Amyloid imaging in atypical presentations of Alzheimer's disease. Curr Neurol Neurosci Rep (2013) 0.85
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Front Neurosci (2015) 0.84
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84
(18)F-florbetaben Aβ imaging in mild cognitive impairment. Alzheimers Res Ther (2013) 0.84
Fluorinated Benzofuran Derivatives for PET Imaging of β-Amyloid Plaques in Alzheimer's Disease Brains. ACS Med Chem Lett (2010) 0.84
Brain PET in the diagnosis of Alzheimer's disease. Clin Nucl Med (2014) 0.84
Memory decline shows stronger associations with estimated spatial patterns of amyloid deposition progression than total amyloid burden. Neurobiol Aging (2013) 0.84
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.83
In vitro and in vivo characterization of two C-11-labeled pet tracers for vesicular acetylcholine transporter. Mol Imaging Biol (2014) 0.83
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci (2013) 0.83
Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis (2014) 0.82
Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm (2013) 0.82
Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. Eur J Nucl Med Mol Imaging (2013) 0.82
Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. ACS Chem Neurosci (2013) 0.82
Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol (2013) 0.82
In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET. Eur J Nucl Med Mol Imaging (2009) 0.82
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther (2011) 0.82
A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.81
Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging (2015) 0.81
Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects. Eur J Nucl Med Mol Imaging (2014) 0.80
Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. Neurol Sci (2016) 0.80
The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging (2012) 0.80
Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. J Alzheimers Dis (2011) 0.80
Quantitative amyloid imaging using image-derived arterial input function. PLoS One (2015) 0.80
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 0.80
PET probes beyond (18)F-FDG. J Biomed Res (2014) 0.79
Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques. ACS Med Chem Lett (2013) 0.79
Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79
Clinical and research applications of simultaneous positron emission tomography and MRI. Br J Radiol (2013) 0.79
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med (2012) 0.79
Synthesis and evaluation of indolinyl- and indolylphenylacetylenes as PET imaging agents for beta-amyloid plaques. Bioorg Med Chem Lett (2008) 0.79
Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol (2010) 17.30
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 7.34
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest (2009) 7.09
Probabilistic Boolean Networks: a rule-based uncertainty model for gene regulatory networks. Bioinformatics (2002) 6.90
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
The Accelerated Child Survival and Development programme in west Africa: a retrospective evaluation. Lancet (2010) 6.56
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
The four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity. Sci Transl Med (2010) 4.78
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Concern Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation (2002) 4.16
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
Stargazin modulates AMPA receptor gating and trafficking by distinct domains. Nature (2005) 3.88
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc Natl Acad Sci U S A (2008) 3.69
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Shell-isolated nanoparticle-enhanced Raman spectroscopy. Nature (2010) 3.64
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (2013) 3.27
Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst (2003) 3.21
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ (2009) 3.10
Multilevel modelling of medical data. Stat Med (2002) 3.05
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet (2010) 3.02
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature (2013) 3.00
Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. Eur Urol (2012) 2.95
Street lighting disturbs commuting bats. Curr Biol (2009) 2.95
High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol (2008) 2.92
Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci (2009) 2.90
Levels and trends in under-5 mortality, 1990-2008. Lancet (2009) 2.86
Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med (2010) 2.86
Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer (2009) 2.85
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
GTPase activation of elongation factor EF-Tu by the ribosome during decoding. EMBO J (2009) 2.71
A primer of amyloid nomenclature. Amyloid (2007) 2.70
Nitrogen fixation island and rhizosphere competence traits in the genome of root-associated Pseudomonas stutzeri A1501. Proc Natl Acad Sci U S A (2008) 2.70
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol (2006) 2.68
Quantized anomalous Hall effect in magnetic topological insulators. Science (2010) 2.67
The mechanical behaviors of polytetrafluorethylene/Al/W energetic composites. J Phys Condens Matter (2009) 2.64
Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res (2012) 2.61
Faster STORM using compressed sensing. Nat Methods (2012) 2.61
Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol (2012) 2.57
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Structural variation in two human genomes mapped at single-nucleotide resolution by whole genome de novo assembly. Nat Biotechnol (2011) 2.45
Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. Environ Health Perspect (2012) 2.42
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science (2013) 2.34
The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4. Curr Biol (2008) 2.33
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement (2013) 2.31
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One (2008) 2.28
In silico microdissection of microarray data from heterogeneous cell populations. BMC Bioinformatics (2005) 2.26
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathol (2014) 2.25
Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int (2013) 2.22
Enhanced fluorescence emission from quantum dots on a photonic crystal surface. Nat Nanotechnol (2007) 2.18
Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest (2010) 2.17
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16